Adam Frymoyer1, Travis L Piester, K T Park. 1. *Department of Pediatrics, Division of Neonatal and Developmental Medicine †Department of Pediatrics, Division of Gastroenterology, Stanford University School of Medicine, Palo Alto, CA.
Abstract
OBJECTIVES: Standard infliximab maintenance dosing of 5 mg/kg every 8 weeks may be inadequate to consistently achieve sufficient drug exposure to minimize loss of response or treatment failure in pediatric Crohn disease (CD). We aimed to determine the predicted infliximab trough concentrations in children with CD during maintenance therapy and the percentage of patients achieving target trough concentration >3 μg/mL. METHODS: A Monte Carlo simulation analysis was constructed using a published population pharmacokinetic model based on data from 112 children in the REACH trial. We assessed maintenance dosing strategies of 5, 7.5, and 10 mg/kg at dosing intervals of every 4, 6, and 8 weeks for children that differed by age, weight, albumin level, and concomitant immunomodulator therapy. RESULTS: Based on the index case of a 10-year-old with CD receiving standard infliximab dosing with concomitant immunomodulator therapy, the median (interquartile range) simulated infliximab trough concentration at week 14 was 1.3 (0.5-2.7) μg/mL and 2.4 (1.0-4.8) μg/mL for albumin levels of 3 and 4 g/dL, respectively. Among 1000 simulated children in the model, trough concentration >3 μg/mL at week 14 was achieved 21% and 41% of the time for albumin levels of 3 and 4 g/dL, respectively. CONCLUSIONS: Standard infliximab maintenance dosing in children with CD is predicted to frequently result in inadequate exposure, especially when albumin levels are low. Optimized dosing strategies for individual patients are needed to achieve sufficient drug exposure during infliximab maintenance therapy.
OBJECTIVES: Standard infliximab maintenance dosing of 5 mg/kg every 8 weeks may be inadequate to consistently achieve sufficient drug exposure to minimize loss of response or treatment failure in pediatric Crohn disease (CD). We aimed to determine the predicted infliximab trough concentrations in children with CD during maintenance therapy and the percentage of patients achieving target trough concentration >3 μg/mL. METHODS: A Monte Carlo simulation analysis was constructed using a published population pharmacokinetic model based on data from 112 children in the REACH trial. We assessed maintenance dosing strategies of 5, 7.5, and 10 mg/kg at dosing intervals of every 4, 6, and 8 weeks for children that differed by age, weight, albumin level, and concomitant immunomodulator therapy. RESULTS: Based on the index case of a 10-year-old with CD receiving standard infliximab dosing with concomitant immunomodulator therapy, the median (interquartile range) simulated infliximab trough concentration at week 14 was 1.3 (0.5-2.7) μg/mL and 2.4 (1.0-4.8) μg/mL for albumin levels of 3 and 4 g/dL, respectively. Among 1000 simulated children in the model, trough concentration >3 μg/mL at week 14 was achieved 21% and 41% of the time for albumin levels of 3 and 4 g/dL, respectively. CONCLUSIONS: Standard infliximab maintenance dosing in children with CD is predicted to frequently result in inadequate exposure, especially when albumin levels are low. Optimized dosing strategies for individual patients are needed to achieve sufficient drug exposure during infliximab maintenance therapy.
Authors: Stephen B Hanauer; Carrie L Wagner; Mohan Bala; Lloyd Mayer; Suzanne Travers; Robert H Diamond; Allan Olson; Warren Bao; Paul Rutgeerts Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382
Authors: J S Hyams; F Mandel; G D Ferry; J D Gryboski; P M Kibort; B S Kirschner; A M Griffiths; A J Katz; J T Boyle Journal: J Pediatr Gastroenterol Nutr Date: 1992-02 Impact factor: 2.839
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: K T Park; Richard B Colletti; David T Rubin; Bal K Sharma; Amy Thompson; Andrew Krueger Journal: Am J Gastroenterol Date: 2015-07-21 Impact factor: 10.864
Authors: Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer Journal: N Engl J Med Date: 2004-02-26 Impact factor: 91.245
Authors: Niels Vande Casteele; Reena Khanna; Barrett G Levesque; Larry Stitt; G Y Zou; Sharat Singh; Steve Lockton; Scott Hauenstein; Linda Ohrmund; Gordon R Greenberg; Paul J Rutgeerts; Ann Gils; William J Sandborn; Séverine Vermeire; Brian G Feagan Journal: Gut Date: 2014-10-21 Impact factor: 23.059
Authors: Adam Frymoyer; Daniël R Hoekman; Travis L Piester; Tim G de Meij; Thalia Z Hummel; Marc A Benninga; Angelika Kindermann; K T Park Journal: J Pediatr Gastroenterol Nutr Date: 2017-12 Impact factor: 2.839
Authors: Laura E Bauman; Ye Xiong; Tomoyuki Mizuno; Philip Minar; Tsuyoshi Fukuda; Min Dong; Michael J Rosen; Alexander A Vinks Journal: Inflamm Bowel Dis Date: 2020-02-11 Impact factor: 5.325
Authors: Joseph A Picoraro; Dale Lee; Caren A Heller; Alandra Weaver; Jeffrey S Hyams; Laurie S Conklin; Anthony Otley; David Ziring; Subra Kugathasan; Joel R Rosh; Andrew Mulberg; Lee A Denson; Michael D Kappelman; Andrew B Grossman; Athos Bousvaros; K T Park Journal: Inflamm Bowel Dis Date: 2019-01-01 Impact factor: 5.325
Authors: Travis Piester; Adam Frymoyer; Megan Christofferson; Helen Yu; Dorsey Bass; K T Park Journal: Inflamm Bowel Dis Date: 2018-01-18 Impact factor: 5.325